Introduction
Pneumocystis jirovecii is an airborne fungus which exclusively colonises the respiratory tract of humans. In immunocompromised individuals it may cause pneumocystis pneumonia (PCP), which typically exhibits an insidious course in HIV-infected individuals and a more fulminant course in non-HIV-infected individuals [1] [2] [3] [4] [5] [6] [7] [8] . P. jirovecii polymerase chain reaction of bronchoalveolar lavage (BAL) specimens is the current gold standard diagnostic test for PCP in these patients [9] . Bortezomib is a reversible mammalian 26S proteosome inhibitor used for remission induction and maintenance in multiple myeloma. It has been implicated in several cases of pulmonary disease and one case of PCP has been reported [10] [11] [12] . This paper presents three probable cases of PCP in patients receiving bortezomib therapy.
Presentation of cases
Written informed consent was obtained from the patient or, in cases where the patient did not have the capacity to give informed consent, from their next of kin for publication of this case series. A copy of the written consent is available for review by the Editorin-Chief of this journal on request.
Case 1
A 76-year-old male with multiple myeloma presented with malaise, confusion, pleuritic chest pain, dyspnoea, non-productive cough, and fevers for ten days. His past medical history included; type 2 diabetes mellitus, iatrogenic primary adrenal insufficiency, Parkinson disease, ischaemic heart disease, and non-melanoma skin cancers. Fourteen days previously, he had commenced his first cycle of cyclophosphamide 500 mg Introduction: This paper presents three probable cases of pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myeloma. Presentation of cases: Three patients receiving bortezomib therapy for multiple myeloma presented with dyspnoea, non-productive cough, and fevers. These patients deteriorated despite receiving broadspectrum antibiotic therapy with piperacillin + tazobactam and azithromycin and an assortment of other antimicrobials but promptly responded to sulfamethoxazole + trimethoprim therapy. Only one of the patients exhibited a positive Pneumocystis jirovecii PCR test but testing was sub-optimal. Discussion: Although only one of the patients exhibited a positive sputum P. jirovecii PCR test, the diagnosis of PCP in these three patients is supported by their; clinical and radiological features consistent with PCP, deterioration despite receiving broad-spectrum antibiotic therapy, and prompt responses to sulfamethoxazole + trimethoprim therapy. In the patients with negative P. jirovecii PCR bronchoalveolar lavage specimens were not obtained as these patients were deemed too high risk to undergo the procedure. Although the three patients were also receiving dexamethasone therapy, the doses and durations were at the threshold of those expected to cause PCP. Conclusion: 26S proteosome inhibitor therapy for multiple myeloma may be a risk factor for PCP and clinicians should adopt a high level of suspicion for PCP in patients receiving these medications until conclusive evidence is obtained. Fig. 1) . Two blood culture sets demonstrated nil growth. Chlamydia pneumoniae and Mycoplasma pneumoniae serology and urine Legionella and Pneumococcal antigen tests were negative. After receiving benzylpenicillin 1.2 g intravenously every 6 h and doxycycline 100 mg orally every 12 h for two days, the patient did not improve clinically. The antimicrobial regimen was changed to piperacillin + tazobactam 4 g + 0.5 g intravenously every 8 h and azithromycin 500 mg intravenously every 24 h. He was also transfused with two units of packed red blood cells. Five days later he continued to exhibit hypoxaemia with a SpO 2 of 88% on room air and fevers of 37.8 8C. The antibiotic regimen was again changed to sulfamethoxazole + trimethoprim 1600 + 320 mg orally every 8 h. An expectorated sputum specimen obtained one day later exhibited a negative P. jirovecii b-tubulin real-time polymerase chain reaction (qPCR) test. BAL specimens could not be obtained as the patient's respiratory failure and frailty precluded bronchoscopy. P. jirovecii microscopy was not ordered. Over the following five days the patient improved clinically and his serum CRP concentration normalised. He continued oral sulfamethoxazole + trimethoprim to complete a total of 21 days of therapy.
Case 2
A 55-year-old female with multiple myeloma presented with malaise, dyspnoea, non-productive cough, and fevers for two days. Her past medical history included; chronic obstructive pulmonary disease, hypertension, gastro-oesophageal reflux disease, recurrent herpes zoster, non-melanoma skin cancers, major depressive disorder, and appendicectomy. Eighteen days previously, she had commenced her third cycle of doxorubicin 28 mg orally on days one and four and bortezomib 1.8 mg subcutaneously and dexamethasone 20 mg orally on days one, four, eight, and 11. She was tachycardic at 137 beats per minute and febrile at 37.7 8C but neither hypotensive nor hypoxaemic. (Fig. 2) . Three blood culture sets demonstrated nil growth. C. pneumoniae and M. pneumoniae serology and urine Legionella and Pneumococcal antigen tests were negative. After receiving piperacillin + tazobactam 4 + 0.5 g intravenously every 8 h and azithromycin 500 mg intravenously every 24 h for three days the patient did not improve and exhibited a SpO 2 of 80% and a PaO 2 of 59.7 mmHg whilst receiving oxygen at a rate of 15 L/ min via non-rebreather mask and a fever of 39.1 8C. An expectorated sputum specimen exhibited a negative P. jirovecii immunofluorescence test but a positive b-tubulin qPCR test. The antibiotic regimen was changed to sulfamethoxazole + trimethoprim 1200 + 240 mg intravenously every 8 h. After five days the patient improved clinically and her serum CRP concentration normalised. She continued sulfamethoxazole + trimethoprim 800 + 160 mg orally every 6 h to complete a total of 21 days of therapy. 
Case 3
A 74-year-old male with multiple myeloma presented with dyspnoea, non-productive cough, right-sided pleuritic chest pain, and fevers for one day. His medical history also included; gastrooesophageal reflux disease, peptic ulcer disease, recurrent herpes zoster, gout, glaucoma, and inguinal hernia repair. Nine days previously, he had commenced his fourth cycle of cyclophosphamide 500 mg intravenously on day one and bortezomib 2.2 mg subcutaneously and dexamethasone 20 mg orally on days one, four, eight, and 11. He was tachycardic at 110 beats per minute, hypotensive at 86/53 mmHg, tachypnoeic at 26 breaths per minute, hypoxaemic with a SpO 2 of 93% and a PaO 2 of 63.5 mmHg whilst receiving oxygen at a rate of 15 L/min via non-rebreather mask, and febrile at 38. tests. BAL specimens could not be obtained as the patient's respiratory failure and septic shock precluded bronchoscopy. After four days, the patient improved clinically and the blood WCC and serum CRP concentration normalised. He was discharged to home five days later and continued sulfamethoxazole + trimethoprim 1600 + 320 mg orally every 8 h to complete a total of 21 days of therapy.
Discussion
Although a positive P. jirovecii sputum PCR test result was only obtained in case 2, the clinical and radiological features observed in all three cases were consistent with PCP. All three cases deteriorated despite receiving broad-spectrum antibiotic therapy with piperacillin + tazobactam and azithromycin and an assortment of other antimicrobials, suggesting the presence of a pathogen resistant to these agents. Although pneumonia due to Toxoplasmosis gondii and viruses may be clinically and radiologically indistinguishable from PCP, it was thought that PCP was the most likely diagnosis. All three cases responded promptly to sulfamethoxazole + trimethoprim therapy.
The paucity of investigation results supporting the diagnosis of PCP in these cases may be attributed to the lack of appropriate investigations. No investigations for the identification of P. jirovecii were performed prior to the commencement of sulfamethoxazole + trimethoprim therapy in cases 1 and 3. Furthermore, expectorated and induced sputum specimens were tested in all three cases because the high risk of respiratory deterioration precluded bronchoscopy to obtain BAL specimens. P. jirovecii PCR testing of induced sputum specimens exhibits a sensitivity of 78.9% and a specificity of 89.0% compared with BAL specimens in HIVinfected individuals [13] . The lower fungal burden of non-HIVinfected individuals with PCP compared with HIV-infected individuals may also have contributed to the lack of evidence to confirm the diagnosis of PCP in cases 1 and 3 [14, 15] .
All three cases received oral dexamethasone therapy at doses which may precipitate PCP, so these cases cannot be directly attributed to treatment with bortezomib. However, the doses of dexamethasone therapy in all three cases were at the threshold of those expected to cause PCP, equivalent to 20 mg of prednisone daily for greater than four weeks [16, 17] .
A review of the literature identified one reported case of PCP caused by bortezomib [13] and no reported cases of PCP caused by carfilzomib, a second generation 26S proteosome inhibitor. Both agents inhibit the chymotrypsin-like activity of the mammalian 26S proteosome, thereby preventing proteolysis of ubiquitinated proteins and causing activation of signalling cascades, cell-cycle arrest, and apoptosis [18] . As P. jirovecii is an obligate intracellular fungus, it is possible that failure of host cell apoptosis may facilitate its reproduction and transition from respiratory tract coloniser to pathogen. Furthermore, all three cases exhibited lymphopaenia, which may have predisposed them to developing PCP. Patients receiving bortezomib or carfilzomib therapy for multiple myeloma also exhibit a higher incidence of herpes zoster compared with those receiving dexamethasone therapy, but there does not appear to be any correlation with the lymphocyte count [19] [20] [21] , suggesting that 26S proteosome inhibitors may also predispose to opportunistic infections by impeding lymphocyte function.
In non-HIV-infected individuals, PCP exhibits a mortality rate of 90-100% in the absence of appropriate treatment [22] whilst PCP associated with acute respiratory failure, as observed in the three cases described in this series, exhibits a mortality rate of up to 67% despite appropriate treatment [23] . Guidelines have been developed for the use of PCP prophylaxis with sulfamethoxazole + trimethoprim in patients with cancer [24] and a meta-analysis of 12 randomised controlled trials with 1245 non-HIV-infected patients with immunocompromise observed a 91% relative risk reduction and a number needed to treat of 15 for sulfamethoxazole + trimethoprim PCP prophylaxis with an incidence of adverse effects warranting prophylaxis cessation of 3.1% [25] . There is currently insufficient evidence to support the use of PCP prophylaxis in patients receiving 26S proteosome inhibitor therapy for multiple myeloma. However, in the event that further surveillance confirms the existence of an association between PCP and 26S proteosome inhibitor therapy, PCP prophylaxis may be indicated in these patients.
Conclusion
26S proteosome inhibitor therapy for multiple myeloma may be a risk factor for Pneumocystis jirovecii pneumonia. Clinicians should adopt a high level of suspicion for PCP and may consider lowering the threshold for PCP prophylaxis in patients receiving these medications until conclusive evidence is obtained.
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